From: Risk of hip fracture among older people using antihypertensive drugs: a nationwide cohort study
 | Total cohort | By sex | ||||
---|---|---|---|---|---|---|
Exposed person-days (14Â days) | Â | Â | Women | Men | ||
 | n | SIR (CI) | n | SIR (CI) | n | SIR (CI) |
Thiazide | 16 | 0.9 (0.5–1.5) | 12 | 0.9 (0.5–1.6) | 4 | 0.8 (0.2–2.2) |
Loop diuretic | 104 | 1.5 (1.3–1.9) | 76 | 1.6 (1.2–2.0) | 28 | 1.5 (1.0–2.1) |
Beta blocker | 47 | 1.0 (0.7–1.3) | 32 | 1.0 (0.7–1.3) | 15 | 1.0 (0.6–1.6) |
Calcium channel blocker | 38 | 1.0 (0.7–1.4) | 30 | 1.1 (0.7–1.5) | 8 | 0.8 (0.3–1.5) |
ACE inhibitor | 29 | 1.0 (0.7–1.5) | 24 | 1.3 (0.8–1.9) | 5 | 0.5 (0.2–1.2) |
ACE inhibitor/Thiazide | 2 | 0.4 (0.1–1.6) | 2 | 0.6 (0.1–2.2) | 0 | – |
Angiotensin II receptor blocker | 11 | 1.0 (0.5–1.8) | 11 | 1.0 (0.5–1.8) | 0 | – |
Angiotensin II receptor blocker/Thiazide | 10 | 0.5 (0.2–0.9) | 8 | 0.5 (0.2–1.1) | 2 | 0.4 (0–1.4) |